4.7 Article

Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 143, 期 1, 页码 160-166

出版社

WILEY
DOI: 10.1002/ijc.31383

关键词

lung cancer; cell culture; epithelial cells; basal cells; stem/progenitor cells

类别

资金

  1. Cancer Research UK [C11496/A17786]
  2. CRUK Lung Cancer Centre of Excellence
  3. Roy Castle Lung Cancer Foundation
  4. Wellcome Trust [WT209199/Z/17, FC001169, FC001202]
  5. Stand Up To Cancer (SU2C)
  6. Rosetrees Trust
  7. NovoNordisk Foundation [16584]
  8. Prostate Cancer Foundation
  9. Breast Cancer Research Foundation (BCRF)
  10. European Research Council (THESEUS)
  11. Marie Curie Network PloidyNet
  12. National Institute for Health Research
  13. University College London Hospitals Biomedical Research Centre
  14. CRUK UCL Experimental Cancer Medicine Centre
  15. Wellcome Trust Senior Fellow in Clinical Science [WT107963/Z/15/Z]
  16. Francis Crick Institute [FC001169, FC001202]
  17. UK Medical Research Council [FC001169, FC001202]
  18. MRC [G108/596] Funding Source: UKRI

向作者/读者索取更多资源

Pre-clinical non-small cell lung cancer (NSCLC) models are poorly representative of the considerable inter-and intra-tumor heterogeneity of the disease in patients. Primary cell-based in vitro models of NSCLC are therefore desirable for novel therapy development and personalized cancer medicine. Methods have been described to generate rapidly proliferating epithelial cell cultures from multiple human epithelia using 3T3-J2 feeder cell culture in the presence of Y-27632, a RHO-associated protein kinase (ROCK) inhibitor, in what are known as conditional reprograming conditions (CRC) or 3T3 + Y. In some cancer studies, variations of this methodology have allowed primary tumor cell expansion across a number of cancer types but other studies have demonstrated the preferential expansion of normal epithelial cells from tumors in such conditions. Here, we report our experience regarding the derivation of primary NSCLC cell cultures from 12 lung adenocarcinoma patients enrolled in the Tracking Cancer Evolution through Therapy (TRACERx) clinical study and discuss these in the context of improving the success rate for in vitro cultivation of cells from NSCLC tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据